Table 2.
Antibody response data in dialysis patients after the second dose of mRNA vaccines
| Author | Year | Country | Type of study | Number of cases | Number of positive cases (%) | Number of the control group | Number of positive controls (%) | Vaccine type | Antibody type | Timing post second dose (days) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Grupper et al. 23 | 2021 | Israel | Case‐Control | 56 | 54 (96%) | 95 | 95 (100%) | BNT162b2 | Anti–RBD IgG | 30 |
| 2 | Speer et al. 8 | 2021 | Germany | Case‐Control | 17 | 14 (82%) | 46 | 46 (100%) | BNT162b2 | Anti‐S1 IgG | 18–22 |
| 3 | Frantzen et al. 24 | 2021 | France | Cohort | 244 | 221 (91%) | None | None | BNT162b2 | Anti‐S IgG | 30 |
| 4 | Simon et al. 25 | 2021 | Austria | Case‐Control | 81 | 74 (91.35%) | 80 | 80 (100%) | BNT162b2 | Anti‐S total | 21 |
| 5 | Jahn et al. 26 | 2021 | Germany | Case‐Control | 72 | 67 (93%) | 16 | 16 (100%) | BNT162b2 | Anti‐S IgG | 14 |
| 6 | Yau et al. 14 | 2021 | Canada | Case‐Control | 72 | 69 (96%) | 35 | 35 (100%) | BNT162b2 | Anti S‐IgG | 14 |
| 7 | Attias et al. 15 | 2021 | France | Cohort | 52 | 43 (82%) | None | None | BNT162b2 | Anti‐S1 IgG | 21 |
| 8 | Schrezenmeier et al. 27 | 2021 | Germany | Case‐Control | 36 | 32 (88.9%) | 44 | 40 (91%) | BNT162b2 | Anti‐RBD IgG | 21 |
| 9 | Agur et al. 28 | 2021 | Israel | Prospective Cohort | 122 | 114 (93.4%) | None | None | BNT162b2 | Anti‐S IgG | 36 |
| 10 | Arevalo et al. 29 | 2021 | Germany | Case‐Control | 44 | 31 (70/5%) | 35 | 35 (100%) | BNT162b2 | Anti‐S1 IgG | 21–28 |
| 11 | Longlune et al. 16 | 2021 | France | Cohort | 77 | 64 (83.11%) | NONE | NONE | BNT162b2 | Anti‐RBD TOTAL | 30 |
| 12 | Strengert et al. 30 | 2021 | Germany | Case‐Control | 81 | 95% | 34 | 34 (100%) | BNT162b2 | Anti‐S1 IgG | 21 |
| 13 | Lacson et al. 31 | 2021 | United States | Cohort | 148 | 130 (88.1%) | None | None | BNT162b2 | Anti‐RBD IgG | ≥14 |
| 14 | Broseta et al. 32 | 2021 | Spain | Cohort | 75 | 69 (92%) | None | None | BNT162b2 | Anti‐RBD IgG | 21 |
| 15 | Garcia et al. 33 | 2021 | United States | Cohort | 416 | 369 (88.6) | None | None | BNT162b2 | Anti‐RBD IgG | 14–28 |
| 16 | Ducloux et al. 34 | 2021 | France | Cohort | 50 | 45 (90%) | None | None | BNT162b2 | Anti‐RBD IgG | 30 |
| 17 | Garcia et al. 33 | 2021 | United States | Cohort | 1316 | 1247 (94.8) | None | None | mRNA‐1273 | Anti‐RBD IgG | 14–28 |
| 18 | Broseta et al. 32 | 2021 | Spain | Cohort | 100 | 98 (98%) | None | None | mRNA‐1273 | Anti‐RBD IgG | 21 |
| 19 | Lacson et al. 31 | 2021 | United States | Cohort | 18 | 17 (94.4%) | None | None | mRNA‐1273 | Anti‐RBD IgG | ≥14 |
| 20 | Espi et al. 18 | 2021 | France | Case‐Control | 92 | 73 (79.35) | 26 | 26 (100%) | BNT162b2 | Anti‐RBD IgG | 10–14 |
| 21 | Espi et al. 32 | 2021 | France | Case‐Control | 75 | 63 (84) | 30 | 30 (100%) | BNT162b2 | Anti‐RBD IgG | 10–14 |
| 22 | Weigert et al. 17 | 2021 | Portugal | Case‐Control | 143 | 130 (90.9%) | 143 | 136 (95.1%) | BNT162b2 | Anti S‐IgG | 21 |
| 23 | Stumpf et al. 35 | 2021 | Germany | Cohort | 936 | 908 (97%) | None | None | mRNA‐1273 | Anti‐S1 IgG | 28 |
| 24 | Stumpf et al. 35 | 2021 | Germany | Cohort | 200 | 176 (88%) | None | None | BNT162b2 | Anti‐S1 IgG | 35 |
| 25 | Clarke et al. 36 | 2021 | England | Cohort | 281 | 248 (88.3%) | None | None | BNT162b2 | Anti S‐IgG | ≥14 |
| 26 | Dulovic et al. 37 | 2021 | Germany | 76 | 72 | 23 | 23 | BNT162b2 | Anti‐RBD IgG | 21 | |
| 27 | Hsu et al. 38 | 2021 | USA | Cohort | 437 | 381 | None | None | BNT162b2 | Anti‐RBD IgG | 14 |
| 28 | Bertrand et al. 39 | 2021 | France | Cohort | 45 | 8 (88.9%) | None | None | BNT162b2 | Anti‐S1 IgG | 14 |
| 29 | Danthu et al. 40 | 2021 | France | Cohort | 78 | 59 (85.5) | 7 | 7 | BNT162b2 | Anti‐S IgG | 14 |
| 30 | Duarte et al. 20 | 2021 | Portugal | Cohort | 42 | 6 (14%) | None | None | BNT162b2 | Anti‐S IgG | 21 |
| 31 | Zitt et al. 22 | 2021 | Austria | Cohort | 48 | 47(97.9%) | None | None | BNT162b2 | Anti‐S IgG | 14 |
| 32 | Paal et al. 41 | 2021 | Germany | Cohort | 179 | 173 (96.6) | 70 | 68 (97.1) | BNT162b2 | Anti‐S IgG | 21 |
| 33 | Giot et al. 42 | 2021 | France | Cohort | 71 | 55 (77%) | None | None | BNT162b2 | Anti‐S IgG | 14 |
| 34 | Dekervel et al. 43 | 2021 | France | Cohort | 66 | 50 | None | None | BNT162b2 | Anti‐S IgG | 14 |
| 35 | Labriola et al. 44 | 2021 | Belgium | Case‐Control | 24 | 19 (79%) | 33 | 28 (85%) | BNT162b2 | Anti‐RBD IgG | 28 |
| 36 | Kolb et al. 21 | 2021 | Germany | Cohort | 32 | 28 (88%) | 78 | 73 | BNT162b2 | Anti‐RBD IgG | 14 |
| 37 | Broseta et al. 18 | 2021 | Spain | Cohort | 78 | 74 (94.9) | None | None | mRNA‐1273 | Anti‐S IgG | 21 |
| 38 | Kaiser et al. 45 | 2021 | Austria | Cohort | 77 | 76 (98.7) | None | None | mRNA‐1273 | Anti‐RBD IgG | 21 |
| 39 | Kaiser et al. 45 | 2021 | Austria | Cohort | 39 | 37 (94.8) | None | None | BNT162b2 | Anti‐RBD IgG | 21 |
| 40 | Yanay et al. 46 | 2021 | Israel | Cohort | 127 | 115 (90.5%) | 132 | 132 | BNT162b2 | Anti‐S IgG | 21–35 |
| 41 | Tylicki et al. 47 | 2021 | Poland | Cohort | 91 | 87 (95.6) | None | None | BNT162b2 | Anti‐S IgG | 14–21 |